Obstructive Sleep Apnea Syndrome, Hypoxemia and Endothelial Dysfunction: One Disease or Many?

Chitra Lal1*, Charlie Strange2

1Assistant Professor of Medicine, Medical University of South Carolina, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, 96 Jonathan Lucas Street, CSB 812, MSC 630, Charleston, SC 29425, USA
2Professor of Medicine, Medical University of South Carolina, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, 96 Jonathan Lucas Street, CSB 812, MSC 630, Charleston, SC 29425, USA

Abstract

The significant adverse sequelae of Obstructive Sleep Apnea Syndrome (OSAS) include a higher incidence of stroke, myocardial infarction and neurocognitive deficits. A link between the intermittent hypoxia of OSAS and endothelial dysfunction may explain many of the macrovascular and microvascular complications of OSAS. The pathogenesis of endothelial dysfunction involves an alteration in the levels of pro-inflammatory and pro-atherogenic mediators. As a form of ischemia/reperfusion injury to the endothelium, intermittent hypoxia induces reactive oxygen species and dysregulates vasoactive metabolites including pathways of nitric oxide synthesis. In addition, hypercoagulability and altered leucocyte migration contribute to the spectrum of endothelial dysfunction. The tools for measurement of endothelial dysfunction and its clinical implications are discussed. Endothelial dysfunction can be in part reversed with continuous positive airway pressure. Thus, early recognition and aggressive treatment of OSAS may prevent associated endothelial dysfunction and subsequent complications of this syndrome.

Keywords: Hypoxemia; Endothelial dysfunction; Obstructive sleep apnea syndrome; Atherosclerosis

Abbreviations: OSAS: Obstructive Sleep Apnea Syndrome; VEGF: Vascular Endothelial Growth Factor; IL-8: Interleukin 8; TNF-alpha: Tumor Necrosis Factor-alpha; NO: Nitric Oxide; ICAM-1: Intercellular Adhesion Molecule-1; VCAM-1: Vascular Cell Adhesion Molecule-1; EMPs: Endothelial Microparticles; EPC: Endothelial Progenitor Cell; CPAP: Continuous Positive Airway Pressure

Introduction

Obstructive Sleep Apnea Syndrome (OSAS) is a common disorder which is often underdiagnosed. Since OSAS is a major public health problem, significant interest has been generated in the health impact and long term sequelae of this disease. Common manifestations of OSAS include snoring, excessive daytime sleepiness and fatigue. In addition, emerging data has linked OSAS to neurocognitive deficits such as memory loss and attention deficits [1], hypertension, arrhythmias, coronary artery disease [2], congestive heart failure, stroke [3] and insulin resistance [4]. One link between the diverse clinical manifestations would be a shared pathogenesis associated with macrovascular or microvascular disease.

Hypoxemia and endothelial dysfunction in OSAS

OSAS causes recurrent episodic oxygen desaturation during sleep. Several studies suggest that OSAS also causes endothelial dysfunction [5,6].

The endothelium is a metabolically active layer of cells lining the intima of blood vessels. Dysfunction of the endothelium can be defined as an alteration of any endothelial function including the transport of substances across the vessel wall, maintenance of vascular smooth muscle tone, secretion of anticoagulant factors, and expression of cell adhesion molecules which can cause granulocyte adhesion and migration.

Since endothelial cells line blood vessels, they are the first cells to be exposed to the effects of hypoxia. The response of endothelium to stressors like hypoxia can be adaptive or maladaptive. An adaptive response may prolong cellular survival. A maladaptive response on the other hand, may perpetuate cellular injury and cause adverse sequelae like stroke, myocardial infarction and death [7]. Examples of a maladaptive response include the development of increased vascular permeability after exposure to hypoxia, presumably due to stimulation of vascular endothelial growth factor (VEGF). Hypoxia can also cause a hypercoagulable state, perhaps through the suppression of thrombomodulin which promotes the production of activated protein C.

In addition, intermittent hypoxemia increases levels of a transcription factor, nuclear factor kappa B [8] which upregulates the production of pro-inflammatory and pro-atherogenic mediators like interleukin 8 (IL-8) [9], and tumor necrosis factor-alpha (TNF-alpha) [8]. These in turn, may result in an accelerated atherosclerotic response.

The endothelium also produces several vasoactive mediators such as nitric oxide (NO), prostacyclin, endothelin-1 and thromoxane. While NO and prostacyclin have vasodilator properties, endothelin-1 and thromboxane are vasoconstrictors. An imbalance of these factors can alter the vascular smooth muscle tone [10]. OSAS decreases endothelial nitric oxide synthase activity [11]. Thus, a heightened vasoconstrictor response may decrease blood flow to critical organs such as the heart and the brain. In addition, NO has anti-inflammatory properties and inhibition of NO production can heighten the atherosclerotic response.

A high level of factors such as L-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) has been seen in OSAS patients [12]. These factors indicate an activated endothelium and may also play a role in the hormonal...
imbalances, hypercoagulability and altered leukocyte migration which form a part of the spectrum of endothelial dysfunction.

Intermittent hypoxia followed by reoxygenation is a form of ischemia-reperfusion injury which has been implicated in local and remote tissue destruction. The mechanisms which have been implicated are an increased production of reactive oxygen species, increased markers of systemic inflammation and an altered balance of metabolites implicated in vascular tone.

Whether OSAS can trigger endothelial dysfunction independent of hypoxemia is unclear. Milder degrees of OSAS without significant nocturnal hypoxemia still are associated with adverse clinical sequelae including acute coronary syndrome and stroke. Since no large studies evaluating this specific question are available, this is an area requiring further study.

**Measurement of endothelial dysfunction**

Endothelial dysfunction has been measured in the OSAS population by alterations in microvascular flow or an increase in markers of endothelial damage or repair. Microvascular flow abnormalities have been seen using flow-mediated dilation of the brachial artery [13], pulse wave analysis, pulse wave velocity [14], and laser doppler flowmetry. Flow-mediated dilation of the vasculature is in part due to nitric oxide and occurs in response to an acute increase in blood flow.

Endothelial microparticles (EMPs) are small vesicles which are released from the endothelium in response to various stressors like intermittent hypoxia which can cause endothelial damage. They can be quantified by flow cytometry using specific antibodies against endothelial antigens. In a prospective study, EMPs were found to be elevated in OSAS patients as compared to controls [15]. Furthermore, the levels of EMPs correlated with the severity of OSAS.

Endothelial repair is in part mediated by a circulating endothelial cell called the endothelial progenitor cell (EPC) [16] that can be counted in blood. EPC numbers have been found to be variable in OSAS [17], which may be a reflection of additional factors influencing individual susceptibility to ischemia-reperfusion injury. Currently these tests of endothelial dysfunction are not commonly available and have been used mainly in research protocols.

**Clinical implications of endothelial dysfunction**

The link between endothelial dysfunction, microvascular pathology and macrovascular disease is critical to understand whether markers of endothelial dysfunction are predictive of clinical events. The hope would be that endothelial dysfunction may have great prognostic value as an early surrogate marker of atherosclerosis.

The prevalence of stroke and myocardial infarction in the OSAS population is quite high. In one case control study, the relative risk of stroke in snorers compared to non-snorers was 10.3 [18]. After adjustment for other risk factors like alcohol consumption, hypertension and coronary artery disease, the odds ratio for stroke in OSAS patients was found to be 8 [19]. A higher incidence of stroke in patients with sleep disordered breathing has been found in other studies as well [20,21]. OSAS has been found to be a strong risk factor for coronary artery disease also [22]. Thus the adverse impact of OSAS on health is considerable.

Endothelial dysfunction also can be seen in snorers and patients with mild OSAS [23] although a strong correlation has been found between the degree of endothelial dysfunction and the severity of OSAS [24,25]. Several studies have shown that endothelial dysfunction can be improved with the use of continuous positive airway pressure (CPAP) [26,27]. It would follow that some adverse consequences of OSAS such as stroke and myocardial infarction might be improved by CPAP therapy. A recent randomized, controlled trial assessing the impact of CPAP on ischemic stroke patients showed improved neurological and cardiovascular outcomes over a 2 year period of follow-up in those with moderate to severe OSAS who were initiated on CPAP early as compared to patients who were not treated with CPAP [28].

The role of endothelial dysfunction in pediatric patients with OSAS has also been studied. Endothelial dysfunction has been shown to be present in non-obese children with OSAS when compared to healthy controls [29]. Similar findings have been replicated in several other pediatric studies. On the other hand, a recent negative study showed endothelial dysfunction to be a function of obesity in pre-pubertal children rather than OSAS [30]. One explanation for this finding could be differences in individual susceptibility to the effects of the intermittent hypoxia seen in OSAS due to variable endothelial functional phenotypes and endothelial repair mechanisms [16].

With the currently available data, there is still much work to be done to further understand the mechanisms of endothelial dysfunction in OSAS. Important work remains to disentangle the many confounding comorbidities in the OSAS population that can independently cause abnormalities of endothelial function.

**Conclusion**

Intermittent hypoxemia seen in untreated OSAS is in part responsible for endothelial dysfunction. A strong link between endothelial dysfunction, microvascular flow alterations, and advanced atherosclerosis has been made. Given the strong association of OSAS with cardiovascular and cerebrovascular morbidity, measurement tools for endothelial dysfunction should be brought to the clinic to optimally treat patients with OSAS. Improved OSAS recognition and appropriate CPAP therapy may help to prevent vascular complications and improve the care of OSAS patients.

**References**


